RT Journal Article
SR Electronic
T1 A Real-life Study of the Positive Response to DAA-based Therapies for Hepatitis C in Brazil
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.10.06.20207274
DO 10.1101/2020.10.06.20207274
A1 Vivaldini, Simone Monzani
A1 Abraão Ribeiro, Rachel
A1 Júnior, Gláucio Mosimann
A1 Tonini, Karen Cristine
A1 Pereira, Gerson Fernando Mendes
A1 de Araújo, Wildo Navegantes
YR 2020
UL http://medrxiv.org/content/early/2020/10/08/2020.10.06.20207274.abstract
AB Treating hepatitis C virus (HCV) infections reduces overall mortality and the risk of multiple extrahepatic complications. Direct-acting antivirals (DAAs) are molecules that target specific non-structural proteins of the virus, resulting in the disruption of viral replication and infection. This report describes the activities undertaken to assess the cure of HCV in patients of different age groups, supported by the Viral Hepatitis National Program of the Unified Health System in Brazil.Around 11,000 patients wereevaluated in an electronic retrospective cohort, which used therapeutic schemes with Sofosbuvir (SOF), Daclatasvir (DCV), Simeprevir (SMV), and an association of Ombitasvir, Veruprevir/Ritonavir and Dasabuvir (3D) with or without Ribavirin (RBV), with sustained virologic response (SVR) or viral cure after a 12-week treatment. We conducted logistic regressions to identify factors independently associated with positive response to DAA-based therapies.Among evaluated patients, 57.1% were male; 48.3% identified as white; 78.3% were over 50 years old; 44.1% were from the Southeast region; 47.7% had genotype 1b; and 84.5% were treated for 12 weeks. The SVR rates with DAAs ranged from 87% to 100%. Genotypes 1 and 4 had a better response (96.3 to 100% of SVR) to therapy with DAAs, and genotypes 2 and 3 had SVR of 90.6% to 92.2%. Different treatment periods showed SVR with an average of 95.0% and 95.9% for 12 and 24 weeks, respectively. In the odds ratio assessment, we verified that females were half as likely (OR 0.5; CI 95% 0.4-0.6) to have a negative response to therapy, when compared to males, and that genotypes 2 and 3 were around twice more likely (OR 1.5-2.2; CI 95% 0.7-2.9; 1.2-3.6 and OR 2.7-2.8; CI 95% 2.0-3.8, respectively) to not have SVR after therapy when compared to genotype 1. Patients aged between 50 and 69 years old were 1.2 times (OR 1,2; CI95% 0,7-1,9) more likely to not have SVR when treated with DAAs, when compared to other age groups.This study is the first of this magnitude to be held in a Latin-American country with high SVR results, supported by a free-of-charge universal and public health system. We confirm the high performance of DAA-based therapies which support the Brazilian public health policy decision of adopting them as an important part of the country’s strategy to eliminate HCV by 2030.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe research was carried out with funding from the authors and without funding from the institutions involved.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All studies involving human beings must be evaluated by an institutional review board (IRB) registered with the National Commission for Ethics in Research (CONEP).This study utilized a historical database, and participants names and personal information were kept confidential by substituting these data for an identification number (ID). As a result, the National Committee for Ethics in Research (CONEP) waived the requirement to obtain patients informed written consent and approved the research, which is registered in Brazil under number 2,872,543.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAs mentioned before, this study utilized a historical database, and participants names and personal information were kept confidential by substituting these data for an identification number (ID). As a result, the National Committee for Ethics in Research (CONEP) waived the requirement to obtain patients' informed written consent and approved the research, which is registered in Brazil under number 2,872,543.